Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes

British Journal of Ophthalmology

Volumn 91, Issue 2, 2007, Pages 166-173

  Tatar, Olcay ^a   Shinoda, Kei ^b   Adam, Annemarie ^c   Eckert, Tillmann ^d   Eckardt, Claus ^d   Lucke, Klaus ^e   Deuter, Christoph ^a   Bartz Schmidt, Karl Ulrich ^a   Grisanti, Salvatore ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b National Hospital Organization   (Japan)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Augenklinik der Staedtischen Kliniken   (Germany)

^e UNIVERSITY OF BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CD34 ANTIGEN; CYTOKERATIN 18; ENDOGLIN; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; KI 67 ANTIGEN; TRIAMCINOLONE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINOTOMY; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; E-SELECTIN; ENDOSTATINS; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PIGMENT EPITHELIUM OF EYE; PORPHYRINS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846781434     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.105288     Document Type: Article

References (60)

1. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-93.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999;117:1329-45.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report 3. Arch Ophthalmol 2002;120:1443-54.
5. Verteporfin in Photodynamic Therapy Study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-60.
6. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no, 1. Am J Ophthalmol 2003;136:407-18.
7. Hawkins BS, Bressler NM, Miskala PH, et al. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic Findings SST Report No, 11. Ophthalmology 2004;111:1967-80.
8. Park CH, Toth CA. Macular translocation surgery with 360-degree peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2003;136:830-5.
9. Mirshahi A, Schreyger F, Baatz H, et al. Macular translocation after photodynamic therapy: a case report. Klin Monatsbl Augenheilkd 2005;222:586-9.
10. Fujii GY, de Juan E Jr, Humayun MS, et al. Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy. Am J Ophthalmol 2003;135(:109-12.
11. Glacet-Bernard A, Coscas G, Soubrane G. Pigment epithelial changes in young women treated with photodynamic therapy and limited macular translocation for classic choroidal neovascularisation. Graefe's Arch Clin Exp Ophthalmol 2006;244:1373-6.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
13. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
14. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-76.
15. Kwak N, Okamoto N, Wood J, et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:3158-64.
16. Baffi J, Bymes G, Chan CC, et al. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 2000;41:3582-9.
17. Tatar O, Kaiserling E, Adam A, et al. Consequences of Verteporfin Photodynamic Therapy on Choroidal Neovascular Membranes. Arch Ophthalmol 2006;124:815-23.
18. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
19. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006;142:95-104.
20. ÕReilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
21. Tatar O, Shinoda K, Adam A, et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration. Exp Eye Res 2006;83:329-38.
22. Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:1544-52.
23. Marneros AG, Zambarakji H, She H, et al. Increased laser-induced choroidal neovascularization in mice lacking collagen XVIII/endostatin. Invest Ophthalmol Vis Sci. 2006;47: E-Abstract, 1532.
24. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.
25. Takahashi K, Saishin Y, Saishin Y, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J 2003;17:896-8.
26. Sasano H, Suzuki T. Pathological evaluation of angiogenesis in human tumor. Biomed Pharmacother 2005;59(Suppl 2):S334-6.
27. Yasukawa T, Kimura H, Tabata Y, et al. Active drug targeting with immunoconjugates to choroidal neovascularization. Curr Eye Res 2000;21:952-61.
28. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002;8:119-26.
29. Karak AK, Sarkar C, Chumber S, et al. MIB-1 proliferate index in parathyroid adenoma and hyperplasia. Indian J Med Res 1997;105:235-8.
30. Grisanti S, Tatar O, Canbek S, et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin- photodynamic therapy. Am J Ophthalmol 2004;137:914-23.
31. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.
32. Petermeier K, Tatar O, Inhoffen W, et al. Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br J Ophthalmol 2006;90:1034-9.
33. Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci USA 2004;101:8005-10.
34. Yeh DC, Bula DV, Miller JW, et al. Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. Invest Ophthalmol Vis Sci 2004;45:2368-73.
35. Schmidt-Erfurth U, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 2003;110:1306-14.
36. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003;44:2147-54.
37. Michels S, Hansmann F, Geitzenauer W, et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47:371-76.
38. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2004;242:91-101.
39. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1:182-93.
40. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995;370:203-8.
41. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996;98:1667-75.
42. Wu P, Yonekura H, Li H, et al. Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes. Biochem Biophys Res Commun 2001;288:1149-54.
43. Nasu K, Nishida M, Fukuda J, et al. Hypoxia simultaneously inhibits endostatin production and stimulates vascular endothelial growth factor production by cultured human endometrial stromal cells. Fertil Steril 2004;82:756-9.
44. Dobryansky M, Galiano RD, Cetrulo CL Jr, et al. Endostatin inhibits ischemia-induced neovascularization and increases ischemic tissue loss. Ann Plast Surg 2004;52:512-18.
45. Eriksson K, Magnusson P, Dixelius J, et al. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003;536:19-24.
46. Ergun S, Kilic N, Wurmbach JH, et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001;4:193-206.
47. Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-4.
48. Jia YH, Dong XS, Wang XS. Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice. World J Gastroenterol 2004;10:3361-4.
49. Zatterstrom UK, Felbor U, Fukai N, et al. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 2000;25:97-101.
50. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
51. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
52. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-44.
53. Macpherson GR, Ng SSW, Forbes SL, et al. Anti-angiogenic activity of endostatin is HIF-1- is independent and sensitive to timing of treatment in a human sapheneous vein assay. Mol Cancer Ther 2003;2:845-54.
54. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002;21:1535-44.
55. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001;159:313-20.
56. Shang QL, Ma JX, Wei JS, et al. Experimental choroidal neovascularization is inhibited by subretinal administration of Endostatin. Zhonghua Yan Ke Za Zhi 2004;40:266-71.
57. Balaggan KS, Binley K, Esapa M, et al. EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Therapy 2006;13:1153- 65.
58. Folkman J. Endogeneous angiogenesis inhibitors. APMIS 2004;112:496-507.
59. Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63:8890-8.
60. Pan X, Wang Y, Zhang M, et al. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol 2004;10:1409-14.